Bristol-Myers Squibb Company (BMY) Operating Cash Flow CAGR:N/A(TTM)
The operating cash flow cagr for Bristol-Myers Squibb Company (BMY) is N/A over the latest trailing 12-month period. Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
The operating cash flow CAGR for Bristol-Myers Squibb Company (BMY) stock is N/A over the past 12 months. The 3 year CAGR is 2.87% and the 5 year CAGR is -1.37%. Operating cash flow CAGR measures the compound annual growth rate of the cash Bristol-Myers Squibb Company generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history. The 1-year (TTM) figure is omitted: a one-year rate off a single quarter's base is volatile; the multi-year figures are the reliable read.
BMY Operating Cash Flow CAGR Chart
Bristol-Myers Squibb Company (BMY)
BMY Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $15.19B | $14.16B | $-1.03B | -6.81% | -6.81% |
| 2024 | $13.86B | $15.19B | +$1.33B | +9.60% | +9.60% |
| 2023 | $13.07B | $13.86B | +$794.00M | +6.08% | +6.08% |
| 2022 | $16.21B | $13.07B | $-3.14B | -19.38% | -19.38% |
| 2021 | $14.05B | $16.21B | +$2.15B | +15.34% | +15.34% |
| 2020 | $8.21B | $14.05B | +$5.84B | +71.16% | +71.16% |
| 2019 | $7.07B | $8.21B | +$1.14B | +16.19% | +16.19% |
| 2018 | $5.28B | $7.07B | +$1.79B | +33.95% | +33.95% |
| 2017 | $3.06B | $5.28B | +$2.22B | +72.50% | +72.50% |
| 2016 | $2.10B | $3.06B | +$953.00M | +45.27% | +45.27% |
| 2015 | $3.15B | $2.10B | $-1.04B | -33.13% | -33.13% |
| 2014 | $3.54B | $3.15B | $-397.00M | -11.20% | -11.20% |
| 2013 | $6.94B | $3.54B | $-3.40B | -48.93% | -48.93% |
| 2012 | $4.84B | $6.94B | +$2.10B | +43.41% | +43.41% |
| 2011 | $4.49B | $4.84B | +$349.00M | +7.77% | +7.77% |
| 2010 | $4.07B | $4.49B | +$426.00M | +10.48% | +10.48% |
| 2009 | $3.71B | $4.07B | +$358.00M | +9.66% | +9.66% |
| 2008 | $3.15B | $3.71B | +$554.00M | +17.57% | +17.57% |
| 2007 | $2.08B | $3.15B | +$1.07B | +51.37% | +51.37% |
| 2006 | $1.84B | $2.08B | +$247.00M | +13.45% | +13.45% |
| 2005 | $3.18B | $1.84B | $-1.34B | -42.19% | -42.19% |
| 2004 | $3.51B | $3.18B | $-336.00M | -9.57% | -9.57% |
| 2003 | $945.00M | $3.51B | +$2.57B | +271.64% | +271.64% |
| 2002 | $5.40B | $945.00M | $-4.46B | -82.51% | -82.51% |
| 2001 | $4.65B | $5.40B | +$750.00M | +16.12% | +16.12% |
| 2000 | $4.22B | $4.65B | +$428.00M | +10.13% | +10.13% |
| 1999 | $3.78B | $4.22B | +$442.00M | +11.69% | +11.69% |
| 1998 | $2.48B | $3.78B | +$1.31B | +52.75% | +52.75% |
| 1997 | $2.64B | $2.48B | $-165.00M | -6.25% | -6.25% |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner